Phio Pharmaceuticals Corp. cotiza a 0.92 USD y tiene una capitalización bursátil de $11M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.36 | $-0.34 | $-0.15 | $-0.44 |
| Estimado | $-0.36 | $-0.23 | $-0.47 | $-0.44 |
| Sorpresa | +0.0% | -47.8% | +68.1% | +0.0% |
| Métrica | PHIO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -43.2% | -40.4% | -2.8% |
| ROA | -40.5% | -32.0% | -8.5% |
| Current Ratio | — | 2.84 | — |
| Debt / Equity | — | 0.28 | — |